CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI) (AI-CYP19)
Significance of CYP19 Genetic Polymorphism on Musculoskeletal Symptom & Complication of Aromatase Inhibitor(AI)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Eun Sook Lee, MD, PhD
- Phone Number: 82-2-920-6744
- Email: eslee@korea.ac.kr
Study Locations
-
-
-
Seoul, Korea, Republic of, 136-705
- Recruiting
- Korea University Anam Hopital
-
Contact:
- Eun Sook Lee, MD, PhD
- Phone Number: 82-2-920-6744
- Email: eslee@korea.ac.kr
-
Principal Investigator:
- Eun Sook Lee, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- The patient must sign the informed consent.
- The patient must sign the informed consent of genetic screening test.
- The patient must be between 18 years old and 80 years old who can make a decision independently.
- The patient must be post-menopause status.
- The patient should be the stage 1,2 or 3 of the breast cancer.
- The test result of the estrogen receptor or progesterone receptor is positive, so the patient should be taking the medication of AI (Aromatase Inhibitor).
Exclusion Criteria:
- The patient is pre-menopause status.
- The test result of serum FSH level is below 30mU/ml.
- The test result of the hormone receptor(ER & PR) is negative or unknown.
- Patient's breast cancer stage is 4 which has systemic metastatics.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
CYP19
CYP19 genetic polymorphism
|
Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change of SNPs (PCR & sequencing), Estrogen, Inflammatory Cytokine level
Time Frame: 6, 12 months
|
6, 12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
EORTC (European Organization for Research and Treatment of Cancer)- QOL(Quality of Life)- C30, BR23 & Skeletal pain information, BMI
Time Frame: 3,6,12 months
|
3,6,12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Eun Sook Lee, MD, PhD, Korea University Anam Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Pain
- Neurologic Manifestations
- Breast Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Breast Neoplasms
- Arthritis
- Arthralgia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Anastrozole
- Aromatase Inhibitors
Other Study ID Numbers
Other Study ID Numbers
- AN09021
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.